Use of18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions

British Journal of Haematology

Volumn 128, Issue 6, 2005, Pages 824-829

  Hart, D P ^a   Avivi, I ^a   Thomson, K J ^a   Peggs, K S ^a   Morris, E C ^a   Goldstone, A H ^a   Linch, D C ^a   Ell, P J ^b   Bomanji, J B ^b   Mackinnon, S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Allogeneic transplantation; Donor lymphocyte infusion; Hodgkin lymphoma; Non hodgkin lymphoma; Positron emission tomography

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; DIAZEPAM; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FOLLOW UP; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; LYMPHOCYTE; MALE; NONHODGKIN LYMPHOMA; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; ALLOTRANSPLANTATION; BIOPSY; BONE MARROW TRANSPLANTATION; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; BIOPSY; BONE MARROW TRANSPLANTATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 20144388352     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05388.x     Document Type: Article

References (19)

1. 18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia, 16, 260-267.
2. Branson, K., Chopra, R., Kottaridis, P.D., McQuaker, G., Parker, A., Schey, S., Chakraverty, R.K., Craddock, C., Milligan, D.W., Pettengell, R., Marsh, J.C., Linch, D.C., Goldstone, A.H., Williams, C.D. & Mackinnon, S. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology, 20, 4022-4031.
3. 18F-FDG in Hodgkin's disease for posttreatment evaluation. Journal of Nuclear Medicine, 44, 1225-1231.
4. Hueltenschmidt, B., Sautter-Bihl, M.L., Lang, O., Maul, F.D., Fischer, J., Mergenthaler, H.G. & Bihl, H. (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer, 91, 302-310.
5. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94, 429-433.
6. Jerusalem, G., Beguin, Y., Fassotte, M.F., Belhocine, T., Hustinx, R., Rigo, P. & Fillet, G. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Annals of Oncology, 14, 123-130.
7. Kostakoglu, L., Coleman, M., Leonard, J.P., Kuji, I., Zoe, H. & Goldsmith, S.J. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of Nuclear Medicine, 43, 1018-1027.
8. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Vertuerth, S., Pettengeli, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., de Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 96, 2419-2425.
9. Mackinnon, S., Papadopoulos, E.B., Carabasi, M.H., Reich, L., Collins, N.H., Boulad, F., Castro-Malaspina, H., Childs, B.H., Gillio, A.P. & Kernan, N.A. ( 1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86, 1261-1268.
10. Maloney, D.G., Sandmaier, B.M., Mackinnon, S. & Shizuru, J.A. (2002) Non-myeloablative transplantation. Hematology (American Society of Hematological Educational Program), 2002, 392-421.
11. Mikhaeel, N.G., Timothy, A.R., Hain, S.F. & O'Doherty, M.J. (2000) 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Annals of Oncology, 11(Suppl. 1), 147-150.
12. Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J., Kittner, T., Franke, W.G. & Ehninger, G. (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. British Journal of Haematology, 115, 793-800.
13. Peggs, K.S., Thomson, K., Hart, D.P., Geary, J., Morris, E.C., Yong, K., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103, 1548-1556.
14. 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. British Journal of Haematology, 123, 282-287.
15. 18F]FDG-PET a valid alternative to conventional diagnostic methods? Journal of Clinical Oncology, 19, 414-419.
16. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, 53-59.
17. Thomas, F., Cosset, J.M., Cherel, P., Renaudy, N., Carde, P. & Piekarski, J.D. (1988) Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease. Radiotherapy and Oncology, 11, 119-122.
18. 18F]FDG uptake in PET. European Journal of Nuclear Medicine and Molecular Imaging, 30, 344-353.
19. 18F- fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 98, 2930-2934.